Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.65 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenoxazine SCHEMBL7862 | 0.79 | ALOX5 (1.00) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL6310178 | 0.79 | ALOX5 (1.00) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL29355714 | 0.79 | ALOX5 (1.00) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL28844098 | 0.79 | ALOX5 (1.00) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL25275195 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL5808288 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL29212121 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL20840431 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL31267446 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA | |
| Phenoxazine SCHEMBL3112369 | 0.77 | ALOX5 (0.94) | ALOX5DHODHMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728136-B2 | Such as 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one via coupling piperazine derivative with alkyl halide by heating in solvent free conditions | LUPIN LIMITED (IN) | 2010-06-01 | — | — | US | claimed |
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | LUPIN LIMITED (IN) | 2007-10-11 | — | — | US | claimed |
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| WO-2006011157-A2 | METHODS FOR THE PREPARATION OF ARYL PIPERAZINYL-HETEROCYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2006-02-02 | — | — | WO | claimed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | claimed |
| EP-0900088-A2 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER INC. (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041896-A2 | INCLUSION COMPLEXES OF ARYL-HETEROCYCLIC SALTS | PFIZER INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-5338846-A | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt | PFIZER INC. (US) | 1994-08-16 | — | — | US | claimed |
| EP-0584903-A1 | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1994-03-02 | — | — | EP | claimed |
| US-5206366-A | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1993-04-27 | — | — | US | claimed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | claimed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | claimed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | claimed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238877-A1 | Novel Method for the Preparation of Aryl Piperazinyl-Heterocyclic Compounds | AQP1, AQP3, AQP4 | ALOX5 1058/4885DHODH 626/4885MEN1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.